Atorvastatin in dyslipidaemia of the nephrotic syndrome

Nephrology

Volumn 8, Issue 2, 2003, Pages 61-64

  Valdivielso, Pedro ^a,b   Moliz, Manuel ^a   Valera, Alfonso ^a   Corrales, Miguel A ^a   Sanchez Chaparro, Miguel A ^a   Gonzalez Santos, Pedro ^a  

^a UNIVERSITY OF MÁLAGA   (Spain)

^b UNIVERSIDAD DE MÁLAGA   (Spain)

Author keywords

Atorvastatin; Dyslipidaemia; Nephrotic syndrome

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTITHROMBIN III; ASPARTATE AMINOTRANSFERASE; ATORVASTATIN; AZATHIOPRINE; CALCIUM CHANNEL BLOCKING AGENT; CREATINE KINASE; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXAZOSIN; FIBRINOGEN; GAMMA GLUTAMYLTRANSFERASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ORAL ANTIDIABETIC AGENT; PREDNISONE; TRIACYLGLYCEROL; UREA; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DYSLIPIDEMIA; EDEMA; FEMALE; HUMAN; HYPERLIPIDEMIA; HYPOALBUMINEMIA; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MALE; MEMBRANOUS GLOMERULONEPHRITIS; NEPHROTIC SYNDROME; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEINURIA; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; AGED; ANTICHOLESTEREMIC AGENTS; FEMALE; HEPTANOIC ACIDS; HUMANS; HYPERLIPIDEMIAS; MALE; MIDDLE AGED; NEPHROTIC SYNDROME; PROSPECTIVE STUDIES; PYRROLES;

EID: 0038748064     PISSN: 13205358     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1797.2003.00143.x     Document Type: Article

References (23)

1. Gentine MG, Fellin G, Cofano F et al. Treatment of proteinuric patients with a vegetarian soy diet and fish oil. Clin. Nephrol. 1993; 40: 315-20.
2. Berg AL, Nilsson-Ehle P, Amadottir M Beneficial effects of ACTH on the serum lipoprotein profile and glomerular function in patients with membranous nephropathy. Kidney Int. 1999; 56: 1534-43.
3. Chan PC, Robinson JD, Yeung WC et al. Lovastatin in glomerulonephritis patients with hyperlipidaemia and heavy proteinuria. Nephrol. Dial. Transplant. 1992; 7: 93-9.
4. Prata MM, Nogueira AC, Pinto JR et al. Long-term effect of lovastatin on lipoprotein profile in patients with primary nephrotic syndrome. Clin. Nephrol. 1994; 41: 277-83.
5. Fuiano G, Esposito C, Sepe V et al. Effects of hypercholesterolemia of renal hemodynamics: study in patients with nephrotic syndrome. Nephron 1996; 73: 430-5.
6. Olbricht CJ, Wanner C, Thiery J, Basten A. Sinvastatin in nephrotic syndrome. Sinvastatin Nephrotic Syndrome Study Group. Kidney Int. 1999; 71 (Suppl.):S113-16.
7. Toto RD, Grundy SM, Vega GL. Pravastatin treatment of very low density, intermediate density and low density lipoproteins in hypercholesterolemia and combined hyperlipidemia secondary to the nephrotic syndrome. Am. J. Nephrol. 2000; 20: 12-17.
8. Matzkies FK, Bahner U, Teschner M et al. Efficiency of 1-year treatment with fluvastatin in hyperlipidemic patients with nephrotic syndrome. Am. J. Nephrol. 1999; 19: 492-4.
9. Lea AP, McTavish D. Atorvastatin. A review of its pharmacology and therapeutic potentials in the management of hyperlipidaemias. Drugs 1997; 53: 828-47.
10. Romero R, Calviño J, Rodriguez J, Sánchez-Guisande D. Short-term effect of atorvastatin in hypercholesterolaemic renal-transplant patients unresponsive to other statins. Nephrol. Dial. Transplant. 2000; 15: 1446-9.
11. Mata P, de Oya M, Pérez-Jiménez F, Ros E. Dieta y enfermedades cardiovasculares. Recomendaciones de la Sociedad Española de Arteriosclerosis. Clin. Invest. Arterioscler. 1994; 6: 43-61.
12. Lukaski HC, Johnson PE, Bolonchuk WW, Lykken GI. Assessment of fat-free mass using bioelectrical impedance measurements of the human body. Am. J. Clin. Nutr. 1985; 41: 810-17.
13. Gidez LI, Miller GJ, Burstein M et al. Separation and quantitation of subclasses of human plasma high density lipoprotein by a simple precipitation procedure. J. Lipid Res. 1982; 23: 1206-23.
14. Bachorik PS, Albers JJ. Precipitation methods for quantification of lipoproteins. Meth. Enzymol. 1986; 129: 78-100.
15. Schrott H, Fereshetian AG, Knopp RH et al. A multicenter, placebo-controlled, dose-ranging study of atorvastatin. J. Cardio. vasc. Pharmacol. Ther. 1998; 3: 119-24.
16. Cameron JS. Coagulation and thromboembolic complication in the nephrotic syndrome. Adv. Nephrol. 1984; 13: 75-114.
17. Heinrich J, Balleisen L, Schulte H et al. Fibrinogen and factor VII in the prediction of coronary risk. Results from the PROCAM study in healthy men. Arterioscler. Thromb. 1994; 14: 54-9.
18. Wierzbicki AS, Lumb PJ, Chik G, Crook MA. Comparison of therapy with simvastatin 80 mg and atorvastatin 80 mg in patients with familial hypercholesterolaemia. Int. J. Clin. Pract. 1999; 53: 609-11.
19. Velussi M, Cernigoi AM, Tortul C, Merni M. Atorvastatin for the management of Type 2 diabetic patients with dyslipidaemia. A mid-term (9 months) treatment experience. Diabetes Nutr. Metab. 1999; 12: 407-12.
20. Harris KP, Purkerson ML, Yates J, Klahr S. Lovastatin ameliorates the development of glomerulosclerosis and uremia in experimental nephrotic syndrome. Am. J. Kidney Dis. 1990; 15: 16-23.
21. Moorhead JF, Brunton C, Fernando RL et al. Do glomerular atherosclerosis and lipid-mediated tubulo-interstitial disease cause progressive renal failure in man? Blood Purif. 1996; 14: 58-66.
22. Vázquez-Pérez S, Aragoncillo P, de las Heras N et al. Atorvastatin prevents glomerulosclerosis and renal endothelial dysfunction in hypercholesterolemic rabbits. Nephrol. Dial. Transplant. 2001; 16 (Suppl. 1): S40-4.
23. Joven J, Villabona C, Vilella E et al. Abnormalities of lipoprotein metabolism in patients with the nephrotic syndrome. N. Engl. J. Med. 1990; 323: 579-84.